Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Interpace Diagnostics is focused on developing and commercializing molecular diagn...
Interpace Diagnostics is focused on developing ...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical t...
Terumo Corporation is a manufacturer and suppli...
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.